Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04623775
Title A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium

Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium

Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium

Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium

Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab

Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab

Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab

Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST